This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
February 24-25, 2011, Radisson Warwick Hotel, Philadelphia, PA
Topics to be Addressed Include:
·Practical Considerations for Expanding the Range of Drugs and Vaccines for
Delivery Using Transdermal Systems
·Explore Transdermal Drug Delivery Systems as a Viable Alternative to Oral,
Intra-Muscular or Intra-venous Injection
·Understand How FDA Regulates Transdermal Drug Delivery Technologies for
Investigational and Marketed Products
·Explore Novel Applications of Transdermal Drug Delivery Technologies
·Overcome Obstacles and Achieving Efficacy in Active Transdermal Delivery
Platforms
·Cost Considerations in the Development and Production of Transdermal
Delivery Systems
·Understand Therapeutic Advantages for Transdermal Delivery of
Biopharmaceutical and Vaccines
·Learn How New Technologies are Expanding the Scope of Transdermal
Delivery to Include Hydrophilic Macromolecules
Featuring Representation From:
Eakins and Associates, Inc.
Biologics Consulting Group
BD Technologies
3M Drug Delivery Systems
University of Mississippi
American Association of Pharmaceutical Scientists
Xel Pharmaceuticals, Inc.
University of Kentucky College of Pharmacy
AllTranz Inc.
Polytherapeutics, Inc.
PATH
Topics to be Addressed Include:
·Practical Considerations for Expanding the Range of Drugs and Vaccines for
Delivery Using Transdermal Systems
·Explore Transdermal Drug Delivery Systems as a Viable Alternative to Oral,
Intra-Muscular or Intra-venous Injection
·Understand How FDA Regulates Transdermal Drug Delivery Technologies for
Investigational and Marketed Products
·Explore Novel Applications of Transdermal Drug Delivery Technologies
·Overcome Obstacles and Achieving Efficacy in Active Transdermal Delivery
Platforms
·Cost Considerations in the Development and Production of Transdermal
Delivery Systems
·Understand Therapeutic Advantages for Transdermal Delivery of
Biopharmaceutical and Vaccines
·Learn How New Technologies are Expanding the Scope of Transdermal
Delivery to Include Hydrophilic Macromolecules
Featuring Representation From:
Eakins and Associates, Inc.
Biologics Consulting Group
BD Technologies
3M Drug Delivery Systems
University of Mississippi
American Association of Pharmaceutical Scientists
Xel Pharmaceuticals, Inc.
University of Kentucky College of Pharmacy
AllTranz Inc.
Polytherapeutics, Inc.
PATH
Companies in this article